$ACI

Albertsons suspends fiscal 2026 guidance, launches business review Q2

Albertsons reported a 69% drop in Q2 net income to $51.5M, with sales down 0.1% to $18.89B. Adjusted EPS of $0.36 and revenue beat analyst estimates. The company suspended fiscal 2026 guidance and launched a business review to cut costs and improve strategy, targeting an investor day in spring 2027. Albertsons also declared a $0.17 quarterly dividend and repurchased 26M shares for $387.6M. The company is pursuing a $9.3B lawsuit against Kroger over a failed merger.

Original reporting
Published Oct 13, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Albertsons suspends fiscal 2026 guidance, launches business review Q2 — source image
Decision brief

The 30-second read

$ACIBearishMed
01

Why it matters

The lack of guidance signals operational challenges and may trigger short‑term price weakness, though dividend and buyback activity could cushion the move.

02

Market read

Earnings release with guidance suspension is a material event for ACI, likely driving short‑term volatility.

03

What to watch

Dividend continuation and share repurchases may provide support despite guidance suspension.

Relevance 8/10Novelty 8/10Timing: today

Background

Albertsons posted a modest decline in net income and flat sales, beat earnings estimates, but halted its outlook pending a strategic review.

Company-level read

Ticker impact

$ACIBearishHigh confidence
Context

Albertsons reported Q2 earnings and suspended its fiscal 2026 guidance while launching a business review.

Expected impact

downward pressure as investors price in lack of guidance and operational concerns

Evidence & confidence

The company omitted forward guidance and highlighted cost‑structure issues, which historically triggers negative market reaction for large retailers.

Market effects

Retail sector may see heightened scrutiny on cost‑control and guidance practices.

U.S. grocery and consumer staples markets could experience modest downside pressure.

Limited; primarily affects U.S. listed grocery retailer.

Counterpoint

The business review could uncover hidden upside, making the stock a potential rebound play.

Key entities

  • Albertsons Companies, Inc.

    U.S. grocery retailer reporting earnings and suspending guidance.

  • Susan Morris

    CEO of Albertsons, announced the business review.

  • Meg Whitman

    Appointed executive chair to help refine strategy.

Related articles

$ACIMedAI 8/10

Albertsons Companies Q2 Earnings Call Highlights

Albertsons (ACI) reported Q2 earnings, highlighting a 1.5% decline in core business sales and a 26.8% gross margin. The company plans to accelerate cost savings, including centralized buying and potential headcount reductions, aiming for $2B in savings over three years. Albertsons generated $1.2B in operating cash flow and repurchased $175M in shares. Management is reviewing its portfolio and expects to provide an updated strategy and outlook by Q4.

$KRMedAI 8/10

Grocer demands more than $9B from Kroger after $25B deal collapsed

Albertsons sued Kroger in Delaware, seeking over $9B after their $24.6B merger collapsed. Albertsons claims Kroger failed to secure regulatory approval and breached the agreement. The suit includes a $600M termination fee, $75M in costs, and a premium for stockholders. Kroger allegedly refused to alter its divestment plan.

$ACIMed

Albertsons Stock (ACI) Slumps as Boss Announces Full Business Review and Annual Guidance Delay

Albertsons (ACI) shares fell after CEO Susan Morris announced a full business review and delayed annual guidance. Q2 earnings per share beat estimates at $0.36, but revenue declined slightly to $18.89B. Pharmacy and digital sales grew, while net income dropped to $51.5M. The company also seeks $9B from Kroger over a failed merger. Analysts have a Hold consensus with a $13 price target.

$ACIMed

Transcript: Albertsons Companies Q2 2026 Earnings Conference Call - Albertsons Companies (NYSE:ACI)

Albertsons (NYSE:ACI) reported Q2 2026 identical sales down 0.8%, adjusted EBITDA $784M, and adjusted EPS $0.36. E-commerce sales grew 11%, while pharmacy sales remained strong. The company aims for $2B in cost savings over three years and is reviewing its business to enhance shareholder value. Albertsons generated $1.2B in operating cash flow and repurchased $400M in shares in the first half of 2026.